These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 37277117)

  • 1. Doubling Down on Wnt Signaling to Overcome Myeloma Bone Disease.
    Delgado-Calle J; Roodman GD
    J Bone Miner Res; 2023 Jun; 38(6):812-813. PubMed ID: 37277117
    [No Abstract]   [Full Text] [Related]  

  • 2. Increasing Wnt signaling in the bone marrow microenvironment inhibits the development of myeloma bone disease and reduces tumor burden in bone in vivo.
    Edwards CM; Edwards JR; Lwin ST; Esparza J; Oyajobi BO; McCluskey B; Munoz S; Grubbs B; Mundy GR
    Blood; 2008 Mar; 111(5):2833-42. PubMed ID: 18094333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Wnt signaling in multiple myeloma: a central player in disease with therapeutic potential.
    Spaan I; Raymakers RA; van de Stolpe A; Peperzak V
    J Hematol Oncol; 2018 May; 11(1):67. PubMed ID: 29776381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
    Schmeel FC; Schmeel LC; Kim Y; Schmidt-Wolf IG
    Hematol Oncol; 2014 Dec; 32(4):197-204. PubMed ID: 24470348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Wnt inhibitors and the suppression of bone formation in multiple myeloma].
    Abe M
    Clin Calcium; 2013 Jun; 23(6):867-75. PubMed ID: 23719500
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Production of Wnt inhibitors by myeloma cells: potential effects on canonical Wnt pathway in the bone microenvironment.
    Giuliani N; Morandi F; Tagliaferri S; Lazzaretti M; Donofrio G; Bonomini S; Sala R; Mangoni M; Rizzoli V
    Cancer Res; 2007 Aug; 67(16):7665-74. PubMed ID: 17702698
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Canonical Wnt pathway inhibitor ICG-001 induces cytotoxicity of multiple myeloma cells in Wnt-independent manner.
    Grigson ER; Ozerova M; Pisklakova A; Liu H; Sullivan DM; Nefedova Y
    PLoS One; 2015; 10(1):e0117693. PubMed ID: 25635944
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Aberrantly expressed LGR4 empowers Wnt signaling in multiple myeloma by hijacking osteoblast-derived R-spondins.
    van Andel H; Ren Z; Koopmans I; Joosten SP; Kocemba KA; de Lau W; Kersten MJ; de Bruin AM; Guikema JE; Clevers H; Spaargaren M; Pals ST
    Proc Natl Acad Sci U S A; 2017 Jan; 114(2):376-381. PubMed ID: 28028233
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dkk1-induced inhibition of Wnt signaling in osteoblast differentiation is an underlying mechanism of bone loss in multiple myeloma.
    Qiang YW; Barlogie B; Rudikoff S; Shaughnessy JD
    Bone; 2008 Apr; 42(4):669-80. PubMed ID: 18294945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wnt3/RhoA/ROCK signaling pathway is involved in adhesion-mediated drug resistance of multiple myeloma in an autocrine mechanism.
    Kobune M; Chiba H; Kato J; Kato K; Nakamura K; Kawano Y; Takada K; Takimoto R; Takayama T; Hamada H; Niitsu Y
    Mol Cancer Ther; 2007 Jun; 6(6):1774-84. PubMed ID: 17575106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Syndecan-1 promotes Wnt/β-catenin signaling in multiple myeloma by presenting Wnts and R-spondins.
    Ren Z; van Andel H; de Lau W; Hartholt RB; Maurice MM; Clevers H; Kersten MJ; Spaargaren M; Pals ST
    Blood; 2018 Mar; 131(9):982-994. PubMed ID: 29212806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transcriptional silencing of the Wnt-antagonist DKK1 by promoter methylation is associated with enhanced Wnt signaling in advanced multiple myeloma.
    Kocemba KA; Groen RW; van Andel H; Kersten MJ; Mahtouk K; Spaargaren M; Pals ST
    PLoS One; 2012; 7(2):e30359. PubMed ID: 22363428
    [TBL] [Abstract][Full Text] [Related]  

  • 13. miR-30-5p functions as a tumor suppressor and novel therapeutic tool by targeting the oncogenic Wnt/β-catenin/BCL9 pathway.
    Zhao JJ; Lin J; Zhu D; Wang X; Brooks D; Chen M; Chu ZB; Takada K; Ciccarelli B; Admin S; Tao J; Tai YT; Treon S; Pinkus G; Kuo WP; Hideshima T; Bouxsein M; Munshi N; Anderson K; Carrasco R
    Cancer Res; 2014 Mar; 74(6):1801-13. PubMed ID: 24599134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular mechanism of Wnt signal pathway in multiple myeloma cell line H929 cell autophagy.
    Liu YS; Liu XB; Qiu YY; Lan T; Chen Y
    Eur Rev Med Pharmacol Sci; 2018 Jun; 22(11):3327-3332. PubMed ID: 29917182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Wnt signaling in leukemias and myeloma: T-cell factors are in control.
    Tiemessen MM; Staal FJ
    Future Oncol; 2013 Nov; 9(11):1757-72. PubMed ID: 24156335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Epigenetic dysregulation of Wnt signaling pathway in multiple myeloma.
    Chim CS; Pang R; Fung TK; Choi CL; Liang R
    Leukemia; 2007 Dec; 21(12):2527-36. PubMed ID: 17882284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multi-Targeting DKK1 and LRP6 Prevents Bone Loss and Improves Fracture Resistance in Multiple Myeloma.
    Simic MK; Mohanty ST; Xiao Y; Cheng TL; Taylor VE; Charlat O; Croucher PI; McDonald MM
    J Bone Miner Res; 2023 Jun; 38(6):814-828. PubMed ID: 36987921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antagonistic effect of small-molecule inhibitors of Wnt/β-catenin in multiple myeloma.
    Narayanan BA; Doudican NA; Park J; Xu D; Narayanan NK; Dasgupta R; Mazumder A
    Anticancer Res; 2012 Nov; 32(11):4697-707. PubMed ID: 23155232
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoting effects of MiR-135b on human multiple myeloma cells via regulation of the Wnt/β-catenin/Versican signaling pathway.
    Chen H; Zhao Y; Zhang J; Xie Y; Jin M
    Cytokine; 2021 Jun; 142():155495. PubMed ID: 33765653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Wnt3a signaling within bone inhibits multiple myeloma bone disease and tumor growth.
    Qiang YW; Shaughnessy JD; Yaccoby S
    Blood; 2008 Jul; 112(2):374-82. PubMed ID: 18344425
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.